Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IONIS GCGRRx

Next Previous
X
Search
Drug Profile

IONIS GCGRRx

Alternative Names: IONIS-GCGRRx; ISIS-449884; ISIS-GCGRRx; RBD-4988

Latest Information Update: 27 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals; Suzhou Ribo Life Science
  • Class Antihyperglycaemics; Antisense oligonucleotides
  • Mechanism of Action Gene silencing; Glucagon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 27 Sep 2022 IONIS GCGRRX is still in phase II trials for Type 2 diabetes mellitus in China (PO) (Ionis Pharmaceuticals pipeline, September 2022)
  • 23 Jul 2022 Phase-II development for Type 2 diabetes mellitus is ongoing in China (Ionis Pharmaceuticals pipeline, July 2022)
  • 05 Jan 2017 Efficacy and adverse events data from a phase II trial in Type 2 diabetes released by Ionis Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top